MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of
Thrombotic Risk in Patients with Acute Myocardial Infarction
and Primary Angioplasty

J 2021

MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty

HROMADKA, Milan, Zuzana MOTOVSKA, Ota HLINOMAZ, Petr KALA, Frantisek TOUSEK et. al.

Základní údaje

Originální název

MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty

Autoři

HROMADKA, Milan (203 Česká republika), Zuzana MOTOVSKA (203 Česká republika), Ota HLINOMAZ (203 Česká republika, domácí), Petr KALA (203 Česká republika, domácí), Frantisek TOUSEK (203 Česká republika), Jiří JARKOVSKÝ (203 Česká republika, domácí), Markéta BERANOVÁ (203 Česká republika, domácí), Pavel JANSKY (203 Česká republika), Michal SVOBODA (203 Česká republika, domácí), Iveta KŘEPELKOVÁ (203 Česká republika), Richard ROKYTA (203 Česká republika), Petr WIDIMSKY (203 Česká republika) a Michal KARPISEK (203 Česká republika)

Vydání

JOURNAL OF PERSONALIZED MEDICINE, BASEL, MDPI, 2021, 2075-4426

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30218 General and internal medicine

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.508

Kód RIV

RIV/00216224:14110/21:00121971

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3390/jpm11060508

UT WoS

000666506600001

Klíčová slova anglicky

acute myocardial infarction; risk stratification; microRNA; miR-126-3P; miR-223-3p; antithrombotic therapy individualization

Štítky

14110115, 14110211, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 24. 7. 2023 12:58, Mgr. Tereza Miškechová

Anotace

V originále

Aim. This study was designed to evaluate the relationship between microRNAs (miRNAs), miR-126-3p and miR-223-3p, as new biomarkers of platelet activation, and predicting recurrent thrombotic events after acute myocardial infarction (AMI). Methods and Results. The analysis included 598 patients randomized in the PRAGUE-18 study (ticagrelor vs. prasugrel in AMI). The measurements of miRNAs were performed by using a novel miRNA immunoassay method. The association of miRNAs with the occurrence of the ischemic endpoint (EP) (cardiovascular death, nonfatal MI, or stroke) and bleeding were analyzed. The miR-223-3p level was significantly related to an increased risk of occurrence of the ischemic EP within 30 days (odds ratio (OR) = 15.74, 95% confidence interval (CI): 2.07-119.93, p = 0.008) and one year (OR = 3.18, 95% CI: 1.40-7.19, p = 0.006), respectively. The miR-126-3p to miR-223-3p ratio was related to a decreased risk of occurrence of EP within 30 days (OR = 0.14, 95% CI: 0.03-0.61, p = 0.009) and one year (OR = 0.37, 95% CI: 0.17-0.82, p = 0.014), respectively. MiRNAs were identified as independent predictors of EP even after adjustment for confounding clinical predictors. Adding miR-223-3p and miR-126-3p to miR-223-3p ratios as predictors into the model calculating the ischemic risk significantly increased the predictive accuracy for combined ischemic EP within one year more than using only clinical ischemic risk parameters. No associations between miRNAs and bleeding complications were identified. Conclusion. The miR-223-3p and the miR-126-3p are promising independent predictors of thrombotic events and can be used for ischemic risk stratification after AMI.

Citovat

HROMADKA, Milan, Zuzana MOTOVSKA, Ota HLINOMAZ, Petr KALA, Frantisek TOUSEK, Jiří JARKOVSKÝ, Markéta BERANOVÁ, Pavel JANSKY, Michal SVOBODA, Iveta KŘEPELKOVÁ, Richard ROKYTA, Petr WIDIMSKY a Michal KARPISEK. MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty. JOURNAL OF PERSONALIZED MEDICINE. BASEL: MDPI, 2021, roč. 11, č. 6, s. 1-12. ISSN 2075-4426. Dostupné z: https://dx.doi.org/10.3390/jpm11060508.

@article{1783535,
   author = {Hromadka, Milan and Motovska, Zuzana and Hlinomaz, Ota and Kala, Petr and Tousek, Frantisek and Jarkovský, Jiří and Beranová, Markéta and Jansky, Pavel and Svoboda, Michal and Křepelková, Iveta and Rokyta, Richard and Widimsky, Petr and Karpisek, Michal},
   article_location = {BASEL},
   article_number = {6},
   doi = {http://dx.doi.org/10.3390/jpm11060508},
   keywords = {acute myocardial infarction; risk stratification; microRNA; miR-126-3P; miR-223-3p; antithrombotic therapy individualization},
   language = {eng},
   issn = {2075-4426},
   journal = {JOURNAL OF PERSONALIZED MEDICINE},
   title = {MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty},
   url = {https://www.mdpi.com/2075-4426/11/6/508},
   volume = {11},
   year = {2021}
}

TY  - JOUR
ID  - 1783535
AU  - Hromadka, Milan - Motovska, Zuzana - Hlinomaz, Ota - Kala, Petr - Tousek, Frantisek - Jarkovský, Jiří - Beranová, Markéta - Jansky, Pavel - Svoboda, Michal - Křepelková, Iveta - Rokyta, Richard - Widimsky, Petr - Karpisek, Michal
PY  - 2021
TI  - MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty
JF  - JOURNAL OF PERSONALIZED MEDICINE
VL  - 11
IS  - 6
SP  - 1-12
EP  - 1-12
PB  - MDPI
SN  - 20754426
KW  - acute myocardial infarction
KW  - risk stratification
KW  - microRNA
KW  - miR-126-3P
KW  - miR-223-3p
KW  - antithrombotic therapy individualization
UR  - https://www.mdpi.com/2075-4426/11/6/508
N2  - Aim. This study was designed to evaluate the relationship between microRNAs (miRNAs), miR-126-3p and miR-223-3p, as new biomarkers of platelet activation, and predicting recurrent thrombotic events after acute myocardial infarction (AMI). Methods and Results. The analysis included 598 patients randomized in the PRAGUE-18 study (ticagrelor vs. prasugrel in AMI). The measurements of miRNAs were performed by using a novel miRNA immunoassay method. The association of miRNAs with the occurrence of the ischemic endpoint (EP) (cardiovascular death, nonfatal MI, or stroke) and bleeding were analyzed. The miR-223-3p level was significantly related to an increased risk of occurrence of the ischemic EP within 30 days (odds ratio (OR) = 15.74, 95% confidence interval (CI): 2.07-119.93, p = 0.008) and one year (OR = 3.18, 95% CI: 1.40-7.19, p = 0.006), respectively. The miR-126-3p to miR-223-3p ratio was related to a decreased risk of occurrence of EP within 30 days (OR = 0.14, 95% CI: 0.03-0.61, p = 0.009) and one year (OR = 0.37, 95% CI: 0.17-0.82, p = 0.014), respectively. MiRNAs were identified as independent predictors of EP even after adjustment for confounding clinical predictors. Adding miR-223-3p and miR-126-3p to miR-223-3p ratios as predictors into the model calculating the ischemic risk significantly increased the predictive accuracy for combined ischemic EP within one year more than using only clinical ischemic risk parameters. No associations between miRNAs and bleeding complications were identified. Conclusion. The miR-223-3p and the miR-126-3p are promising independent predictors of thrombotic events and can be used for ischemic risk stratification after AMI.
ER  -

HROMADKA, Milan, Zuzana MOTOVSKA, Ota HLINOMAZ, Petr KALA, Frantisek TOUSEK, Jiří JARKOVSKÝ, Markéta BERANOVÁ, Pavel JANSKY, Michal SVOBODA, Iveta KŘEPELKOVÁ, Richard ROKYTA, Petr WIDIMSKY a Michal KARPISEK. MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty. \textit{JOURNAL OF PERSONALIZED MEDICINE}. BASEL: MDPI, 2021, roč.~11, č.~6, s.~1-12. ISSN~2075-4426. Dostupné z: https://dx.doi.org/10.3390/jpm11060508.

Podrobný výpis o publikaci